Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Stroke Stroke, Acute Brain Injury, Acute 18-90 years old 2. Recent, acute, cortical, hemispheric, ischemic stroke in the MCA distribution without a clinically significant midline shift as detected by MRI as a DWI abnormality. If unable to obtain a MRI scan, patients may be included if there is clear evidence of ischemic cortical involvement in the MCA distribution demonstrated by computed tomography and a clinical exam consistent with cortical involvement. 3. NIHSS 6-15(R) and 6-20 (L) at the time of informed consent. Subjects with a >4-point increase of NIHSS from time of consent (worsening of score) will not be eligible for infusion. 4. Subjects must have a platelet count >100,000/uL, hemoglobin >8gm/dL, absolute lymphocyte count (ALC) ≥ 1200 for African American patients and ≥1500 for all other racial-ethnic groups, and WBC >2,500/uL OR Historical pre-stroke value of ALC ≥ 1200 for African American and ≥1500 for all other racial-ethnic groups within 6 months of stroke -And a post stroke ALC value of ≥ 1000, platelet count >100,000/uL, hemoglobin >8gm/dL and WBC >2,500/uL. 5. Subjects who received tPA or underwent endovascular reperfusion may be included in the study 6. Able to provide consent to study or consent is obtained from the patient's legal representative 7. Subjects of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after intervention so that, in the opinion of the Investigator, they will not become pregnant during the course of the study 8. Is a good candidate for the trial, in the opinion of the Investigator 9. Agrees to participate in follow-up visits 10. ABO/Rh and race matched CBU(s) with a minimum of 0.5 x 10^7 TNCC/kg based on the pre-cryopreservation TNCC is available for infusion 11. Has not had a disease or therapy that would compromise current immune function. 12. Has a serum creatinine ≤2 mg/dL OR Glomerular Filtration Rate (GFR) ≥30mL/min  An individual is ineligible to participate if any of the following apply: Exclusionary Medical Conditions: 1. Medical history of neurological or orthopedic pathology with a deficit as a consequence that results in a modified Rankin Scale >1 before stroke or has a pre existing cognitive deficit 2. Clinically significant and/or symptomatic hemorrhage associated with stroke 3. Evidence of significant midline shift as assessed by CT or MRI who are felt to be at high risk for neurological decompensation or need for decompressive hemicraniectomy due to hemispheric edema 4. New intracranial hemorrhage, edema, or mass effect that may place patient at increased risk for secondary deterioration when assessed prior to infusion 5. Hypotension as defined as the need for IV pressor support of SBP <90 6. Isolated brain stem stroke 7. Pure lacunar stroke 8. At time of consent, patients who are mechanically ventilated or, at the investigator's discretion are felt to be likely to need mechanical ventilation are excluded. 9. Requires a craniotomy 10. Serious psychiatric or neurological disease which could alter evaluation on functional or cognitive scales 11. Active systemic infection that is felt, at the discretion of the Investigator, to place the patient at increased risk for participation in this study 12. Documentation of human immunodeficiency virus positive (HIV+) status in the medical record 13. Active malignancy within 3 years prior to the start of screening excluding skin cancers other than melanoma 14. Known hypercoagulable state or coagulopathy deficiencies such as Factor V Leiden, Antiphospholipid Syndrome (APC), Protein C, Protein S, anticardiolipin antibody, phospholipid syndrome or Sickle Cell Disease 15. History of or currently active autoimmune disease, or current immunomodulatory therapy or a recipient of immunomodulatory therapy in the past year. 16. Concurrent illness or condition that in the opinion of the Investigator might interfere with treatment or evaluation of safety 17. Current or recent history of alcohol or drug abuse, or stroke associated with drug abuse that Investigator feels may impair therapy or assessments 18. Pregnant as documented by blood test Prohibited Concomitant or Prior Therapies 1. Patients currently receiving immunosuppressant drugs, not including glucocorticoid taper, topical/inhaled glucocorticoids 2. History of prior transfusion reaction 3. Currently on dialysis 4. Recipient of bone marrow or organ transplant 5. Hepatic insufficiency (bilirubin >2.5mg/dL or transaminases >5x the ULN) Patients with Gilberts syndrome are eligible for study enrollment if other liver function tests are normal, regardless of bilirubin level 6. Previous or current treatment with angiogenic growth factors, cytokines, gene or stem cell therapy 7. Participating in another interventional clinical trial of an investigational therapy within 30 days of consent. Other Pregnant or lactating women 2. Unable or unwilling to be evaluated for follow-up visits